Image_1_Acoustic tomographic inversion of 3D temperature fields with mesoscale anomaly in the South China Sea.pdf

Acoustic tomographic inversion is based on travel times measured along the transmission paths between all station pairs to reconstruct three-dimensional temperature structures with mesoscale anomalies. In this study, tomographic simulation experiments were designed based on the Hybrid Coordinate Ocean Model (HYCOM) reanalysis data to reconstruct mesoscale phenomena from travel time data obtained from five, seven, and nine stations in the South China Sea over a domain of 100 × 100 km. The travel times for each station pair were calculated in the vertical section using the Bellhop acoustic ray simulation method. Six Empirical orthogonal function (EOF) modes of sound speed along the sound transmission paths in a vertical slice were used to formulate the inversion equations. The horizontal-slice distributions of temperature in the tomography domain were reconstructed using the grid-segmented method for each depth layer. For station-to-station distances greater than 100 km, the performance of inversion was best for the seven-station case rather than for the nine-station case, with the highest horizontal resolution of the three cases. This case study concluded that the seven-station case rather than the nine-station case provided an optimal station number for reconstructing the three-dimensional temperature fields.</p

Nonvolatile n‑Type Doping and Metallic State in Multilayer-MoS₂ Induced by Hydrogenation Using Ionic-Liquid Gating

Manipulation of the carrier density of layered transition-metal dichalcogenides (TMDs) is of fundamental significance for a wide range of electronic and optoelectronic applications. Herein, we applied the ionic-liquid-gating (ILG) method to inject the smallest ions, H+, into layered MoS2 to manipulate its carrier concentration. The measurements demonstrate that the injection of H+ realizes a nonvolatile n-type doping and metallic state in multilayer-MoS2 with a concentration of injection electron of ∼1.08 × 1013 cm–2 but has no effect on monolayer-MoS2, which clearly reveals that the H+ is injected into the interlayer of MoS2, not in the crystal lattice. The H+-injected multilayer-MoS2 was then used as the contact electrodes of a monolayer-MoS2 field effect transistor to improve the contact quality, and its performance has been enhanced. Our work deepens the understanding of the ILG technology and extends its application in TMDs

An Insight into Glyco-Microheterogeneity of Plasma von Willebrand Factor by Mass Spectrometry

Human plasma von Willebrand Factor (VWF) plays essential roles in primary hemostasis in cooperation with other coagulations factors. There is ample indication that glycosylation affects many biological phases during the protein life cycle. However, comprehensive characterization of all probable N-glycosites simultaneous with O-glycosites is still not fully revealed. Thus, the intention of this exploration was to estimate the occupancy of all canonical N-glycosites besides simultaneous characterization of N- and O-glycoforms. An RP–LC–MS/MS system functionalized with CID and HCD tandem mass was utilized to analyze VWF. N-Glycosite occupancy varied along the protein backbone chain. Out of 257 HCD spectra, 181 characterized glycoforms were specified as either N- or O-glycosites. Sequential cleavage of glycosidic bonds along with Human Database mass matching have confirmed the glycoform structures. A total of 173 glycoforms represented most commonly biantennary and infrequently tri- and tetra-antennary N-glycans beside high mannose, hybrid, ABH antigen-terminated, and sulfated N-glycans. Many glycoforms were common across all N-sites. Noteworthy, previously unreported N-glycosites within domain D′(TIL′-E′) showed glycosylation. Moreover, sialylated core 1 and core 2 O-glycans were detected on 2298T. Given subtle characterization of site-specific glycoforms, we can attain a profound understanding of the biological roles of VWF as well as facilitate the production of VWF-based therapeutics